Elias J. Jabbour, MD, MD Anderson
Articles
ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
February 14th 2022Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.
Read More
ASH 2021: Key Data in Chronic Myeloid Leukemia
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
February 7th 2022Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
Read More
ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute;Jae Park, MD, Memorial Sloan Kettering Cancer Center;Elias J. Jabbour, MD, MD Anderson
January 31st 2022Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.
Read More
Latest Updated Articles
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
